Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis

OBJECTIVE: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances. DES...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of endocrinology Vol. 145; no. 6; pp. 685 - 690
Main Authors Ueland, T, Bollerslev, J, Godang, K, Muller, F, Froland, SS, Aukrust, P
Format Journal Article
LanguageEnglish
Published England European Society of Endocrinology 01.12.2001
Subjects
Online AccessGet full text
ISSN0804-4643
1479-683X
DOI10.1530/eje.0.1450685

Cover

Abstract OBJECTIVE: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances. DESIGN: The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR). METHODS: Serum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR). RESULTS: OPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin. CONCLUSIONS: These findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.
AbstractList To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances. The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR). Serum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR). OPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin. These findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.
To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances.OBJECTIVETo investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances.The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR).DESIGNThe study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR).Serum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR).METHODSSerum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR).OPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin.RESULTSOPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin.These findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.CONCLUSIONSThese findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.
OBJECTIVE: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient populations with known or suspected pathology in bone homeostasis, but with differences in the pathogenesis of these disturbances. DESIGN: The study comprised 34 patients with Cushing's syndrome (CS), 24 acromegalic patients, 16 patients with growth hormone deficiency (GHD), 29 HIV-infected patients, 25 patients with common variable immunodeficiency (CVI) and 59 age- and sex-matched healthy controls (CTR). METHODS: Serum levels of tumor necrosis factor (TNF)-alpha, OPG, C-terminal telopeptides of Type-I collagen (CTX-I) and osteocalcin were determined in all study subjects as well as cortisol (CS and CTR) and IGF-I (acromegaly, GHD and CTR). RESULTS: OPG levels were significantly elevated in both CVI (median increase approximately 32%, P < 0.05) and HIV-infected patients with especially high levels in the latter group ( approximately 52%, P < 0.001), significantly correlated with increased TNFalpha levels (r = 0.47, P < 0.02). Also CS patients had elevated serum OPG ( approximately 24%, P < 0.01), significantly correlated with increased serum cortisol (r = 0.35, P < 0.05). In contrast, OPG levels in acromegalic and GHD patients were not different from healthy controls. No relationships were found between OPG levels and CTX-I or osteocalcin. CONCLUSIONS: These findings suggest that enhanced OPG levels may be a compensatory response to enhanced osteoclast activity or negative bone remodeling balance in some conditions, but may also be a parameter of enhanced activity in the OPG system possibly correlated to enhanced activity of other members of the TNF family.
Author Aukrust, P
Godang, K
Muller, F
Bollerslev, J
Froland, SS
Ueland, T
Author_xml – sequence: 1
  givenname: T
  surname: Ueland
  fullname: Ueland, T
– sequence: 2
  givenname: J
  surname: Bollerslev
  fullname: Bollerslev, J
– sequence: 3
  givenname: K
  surname: Godang
  fullname: Godang, K
– sequence: 4
  givenname: F
  surname: Muller
  fullname: Muller, F
– sequence: 5
  givenname: SS
  surname: Froland
  fullname: Froland, SS
– sequence: 6
  givenname: P
  surname: Aukrust
  fullname: Aukrust, P
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11720891$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9LHjEQxkNR6qvtsdcSL95Wk93sbvZYpFVB6EXB25I_szqyu3mbZMW3H6Sf19FXWygIIRkyv2eGeWaf7cxhBsa-SHEs60qcwD0cU6hq0ej6A1tJ1XZFo6ubHbYSWqhCNaraY_sp3QshKRYf2Z6UbSl0J1fsz8XsIpgEnieIy8RDyhDWMWS4hYgzp-MxheghJu7uTDQuU-I3CeyGr-kXSTFnjtO0zMApjQ8mY5h5iPx2XFxwIWZ0AT2HRwcpFcU6pIR2BB4DXdTC0lD8LkxA7Q1V_MR2BzMm-Pz6HrDrH9-vTs-Ly59nF6ffLgurpMiFHbSCYYDBNNLUvjaNbrWFstbKeyWtLw0ob0oFXvuqlWA7pbRtnak7LaWrDtjRti5N_GuBlPsJk4NxNDOEJfVtWYmqVR2BX1_BxU7g-3XEycRN_-YkAcUWcJGGizD8Q0T_vKmeNtVTuN0U8dV_vMP84luOBsd3VYdblcWQHJLvOKAzf3s9M0-WLKki
CitedBy_id crossref_primary_10_1016_j_pnpbp_2013_01_019
crossref_primary_10_1186_s12891_016_1036_5
crossref_primary_10_1161_ATVBAHA_109_184101
crossref_primary_10_1002_jmv_20938
crossref_primary_10_1016_j_bone_2006_06_022
crossref_primary_10_1016_S8756_3282_03_00240_0
crossref_primary_10_1016_j_cytogfr_2004_06_004
crossref_primary_10_1097_01_psy_0000237858_76880_3d
crossref_primary_10_1203_01_pdr_0000196375_47889_5b
crossref_primary_10_1016_j_coemr_2018_02_009
crossref_primary_10_1016_j_ejim_2012_09_007
crossref_primary_10_1007_s00383_009_2325_y
crossref_primary_10_1016_j_ghir_2004_06_002
crossref_primary_10_1093_rheumatology_keq005
crossref_primary_10_1371_journal_pone_0134266
crossref_primary_10_1111_j_1468_1293_2005_00278_x
crossref_primary_10_1038_labinvest_3700701
crossref_primary_10_1016_j_jhsa_2024_12_017
crossref_primary_10_1097_MCG_0000000000001032
crossref_primary_10_1016_j_tem_2020_04_004
crossref_primary_10_1359_JBMR_041126
crossref_primary_10_1371_journal_pone_0173034
crossref_primary_10_1186_1546_0096_8_30
crossref_primary_10_1530_EJE_09_0800
crossref_primary_10_1016_j_metabol_2007_01_004
crossref_primary_10_1210_jcem_87_6_8549
crossref_primary_10_1093_alcalc_agl004
crossref_primary_10_1007_BF03346383
crossref_primary_10_1111_j_1365_2265_2005_02221_x
crossref_primary_10_1111_j_1365_2796_2011_02393_x
crossref_primary_10_1002_cncr_11127
crossref_primary_10_1016_j_fsisyn_2023_100326
crossref_primary_10_1515_CCLM_2002_177
crossref_primary_10_1210_jc_2006_2283
crossref_primary_10_1371_journal_ppat_1004497
crossref_primary_10_1007_s11102_016_0758_6
crossref_primary_10_1016_S0168_8278_02_00435_X
crossref_primary_10_1161_01_ATV_0000204334_48195_6a
crossref_primary_10_1097_TP_0000000000000227
crossref_primary_10_33549_physiolres_934303
crossref_primary_10_1177_000456320203900602
crossref_primary_10_36290_vnl_2024_067
crossref_primary_10_1111_j_1365_2265_2009_03605_x
crossref_primary_10_1111_j_1365_2796_2009_02163_x
crossref_primary_10_1038_sj_ki_5002716
crossref_primary_10_1530_eje_1_01874
crossref_primary_10_1016_j_atherosclerosis_2010_06_027
crossref_primary_10_1159_000357787
crossref_primary_10_3389_fendo_2024_1472680
crossref_primary_10_1007_s11102_022_01256_6
crossref_primary_10_1902_jop_2010_100585
crossref_primary_10_1210_jc_2014_2937
crossref_primary_10_1302_0301_620X_90B8_20861
crossref_primary_10_1016_j_jacc_2004_06_076
crossref_primary_10_1111_cen_12189
crossref_primary_10_1097_QAI_0000000000000725
crossref_primary_10_1007_BF03345601
crossref_primary_10_1007_s00223_009_9275_1
crossref_primary_10_1089_aid_2012_0305
crossref_primary_10_1210_clinem_dgac183
crossref_primary_10_36290_vnl_2017_117
crossref_primary_10_1007_s00198_013_2268_y
crossref_primary_10_1210_er_2018_00005
crossref_primary_10_1111_j_1478_3231_2005_01073_x
crossref_primary_10_1007_s40618_020_01269_7
crossref_primary_10_1097_01_tp_0000209413_45179_f6
crossref_primary_10_1161_CIRCHEARTFAILURE_110_957332
crossref_primary_10_1515_JPEM_2009_22_12_1105
crossref_primary_10_1359_jbmr_2002_17_11_1961
crossref_primary_10_1016_j_bone_2004_04_021
crossref_primary_10_1159_000444638
crossref_primary_10_36290_vnl_2021_073
crossref_primary_10_1016_j_alcohol_2010_09_002
crossref_primary_10_1016_j_metabol_2006_12_018
crossref_primary_10_1016_j_amjcard_2006_08_064
crossref_primary_10_1016_j_maturitas_2006_05_007
crossref_primary_10_1161_01_CIR_0000165119_62099_14
crossref_primary_10_3803_EnM_2023_1782
crossref_primary_10_1186_s12981_017_0162_y
crossref_primary_10_1161_JAHA_117_007009
crossref_primary_10_2177_jsci_34_138
crossref_primary_10_5435_JAAOS_D_16_00123
crossref_primary_10_2310_6650_2006_06019
crossref_primary_10_1038_sj_leu_2403429
crossref_primary_10_1097_QAI_0b013e318295eb1d
crossref_primary_10_1111_j_1365_2265_2010_03884_x
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1530/eje.0.1450685
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1479-683X
EndPage 690
ExternalDocumentID 11720891
10_1530_eje_0_1450685
Genre Journal Article
GroupedDBID ---
-~X
.GJ
08R
0R~
18M
2WC
3O-
4.4
53G
5GY
5RE
5VS
AAPBV
AAPXW
ABLYK
ABOCM
ABPTK
ABSGY
ABSQV
ACGFO
ACNCT
ACPRK
ADBBV
ADDZX
AENEX
AFFNX
AFHIN
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCRHZ
BTFSW
C1A
CS3
DIK
DU5
E3Z
EBS
F9R
GX1
H13
HZ~
IL9
J5H
KQ8
L7B
O9-
OK1
P2P
RHF
ROX
SJN
TBS
TEORI
TR2
VH1
W8F
WOQ
ZA5
ZGI
ZXP
5WD
AABZA
AACZT
AAUAY
AAVAP
AAYXX
ABDFA
ABEJV
ABGNP
ABJNI
ABMNT
ABNHQ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ABXZS
ACUTJ
ADGKP
ADIPN
ADNBA
ADVEK
ADVOB
AEMQT
AFGWE
AFXAL
AGORE
AGQXC
AGUTN
AHMMS
AJBYB
AJEEA
AJNCP
ALXQX
CITATION
EMOBN
KOP
OAUYM
OBOKY
OCZFY
OJZSN
OPAEJ
OVD
OWPYF
.55
AAPGJ
AARHZ
AAWDT
ACFRR
ADQBN
AFYAG
ANFBD
APJGH
ATGXG
CGR
CUY
CVF
ECM
EIF
EJD
INIJC
NPM
PKN
TCN
TMA
VXZ
X7M
7X8
NU-
ID FETCH-LOGICAL-b410t-bf84effefa61a5d5a6878be2584dd41bd2ae4da24ed8d371eb9448b7ca59811c3
ISSN 0804-4643
IngestDate Fri Jul 11 12:13:24 EDT 2025
Wed Feb 19 02:36:15 EST 2025
Thu Apr 24 22:59:34 EDT 2025
Tue Jul 01 02:38:29 EDT 2025
Tue Apr 04 03:22:32 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b410t-bf84effefa61a5d5a6878be2584dd41bd2ae4da24ed8d371eb9448b7ca59811c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://eje.bioscientifica.com/view/journals/eje/145/6/.xml
PMID 11720891
PQID 72303749
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_72303749
pubmed_primary_11720891
crossref_primary_10_1530_eje_0_1450685
crossref_citationtrail_10_1530_eje_0_1450685
bioscientifica_primary_685
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2001-12-01
PublicationDateYYYYMMDD 2001-12-01
PublicationDate_xml – month: 12
  year: 2001
  text: 2001-12-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle European journal of endocrinology
PublicationTitleAlternate Eur J Endocrinol
PublicationYear 2001
Publisher European Society of Endocrinology
Publisher_xml – name: European Society of Endocrinology
References 11720890 - Eur J Endocrinol. 2001 Dec;145(6):681-3
References_xml – reference: 11720890 - Eur J Endocrinol. 2001 Dec;145(6):681-3
SSID ssj0016430
Score 2.013807
Snippet OBJECTIVE: To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized...
To investigate the possible role of osteoprotegerin (OPG) in bone metabolism in humans by measuring serum levels of OPG in five well-characterized patient...
SourceID proquest
pubmed
crossref
bioscientifica
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 685
SubjectTerms Acromegaly - blood
Adult
Aged
Bone and Bones - metabolism
Bone Remodeling
Common Variable Immunodeficiency - blood
Cushing Syndrome - blood
Female
Glucocorticoids - metabolism
Glycoproteins - blood
Glycoproteins - physiology
HIV Infections - blood
Homeostasis
Human Growth Hormone - deficiency
Humans
Hydrocortisone - blood
Immunologic Deficiency Syndromes - blood
Insulin-Like Growth Factor I - analysis
Male
Middle Aged
Osteocalcin - blood
Osteoclasts - physiology
Osteoprotegerin
Peptide Fragments - blood
Procollagen - blood
Receptors, Cytoplasmic and Nuclear - blood
Receptors, Cytoplasmic and Nuclear - physiology
Receptors, Tumor Necrosis Factor
s
Tumor Necrosis Factor-alpha - analysis
Title Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis
URI https://eje.bioscientifica.com/view/journals/eje/145/6/.xml
https://www.ncbi.nlm.nih.gov/pubmed/11720891
https://www.proquest.com/docview/72303749
Volume 145
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBBIINi4dNz8gPZSUprEuT0OxDaBxtMq9S2yY2cUrUnVphPbD-En8Ds5x3aSpqMIkKooieKL-n1xjo-_c0zIm8AVOSY1cXKVc4dJIR0e88xhySjzMpFlkYfByadfwpMx-zQJJr3ezzXV0qoSw-z6t3El_4Mq3ANcMUr2H5BtKoUbcA74whEQhuNfYQwvN2rKwWaE5lazAQZslDrzwjlG9Wmlq82uucQQX5ua-dpYnXN0lUGJohpMMUrEJNa4tDbkYqDV7DA5hWbLqRyo7xhR4DjzEl-jCytMhCZECUW_ljMFzfPldLnV2W8NX1XIEsaqrkN_rGqJZaPafo8-DXSqX3aWr45LaX3cn1u21AGNRx0vhruhCGl6U2tVUVZ5ozd2WBwxh4UmudNQmWGbRYkTxnpn4XZcN3kqLYHXR-nQ7BJkP_ih2a_0xrck8FF8qb6pIVywYASlbpHbXhRpOcDxpJESwYxT72nT9MzmcoUK3nWK3yP3xdTkKNVCsA1jaMsMR1s6Zw_JAztFoYeGb49ITxW7ZO-w4FU5u6IHVIuG9d-1S-6cWm3GHvnRsJFqNtINNlL4NWykHTZScUVbNlLDRtqykZYL2mUj3WQjRTZiE8hGusbGx2R89PHsw4ljd_1wBHNHlSPymKGWKeehywMZ8DCOYqE8sJSlZK6QHldMco8pGUs_cpVIGItFlPEgiV0385-QnQKaekaoFyWc5yrwwggexxVuGXlS-HEGcARy1Cf7XTzSuUnxkgJYffK2xibNbL583LblIsV5M2CbArYpnBps--SgebyuZcuDr2ugUxjKcX2OF6pcLdPI8zEbVNInTw3-bUUwzYDeu_t_6vBzcrd9s16QnWqxUi_BYq7EK03XX-qm0RU
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+serum+osteoprotegerin+in+disorders+characterized+by+persistent+immune+activation+or+glucocorticoid+excess--possible+role+in+bone+homeostasis&rft.jtitle=European+journal+of+endocrinology&rft.au=Ueland%2C+T&rft.au=Bollerslev%2C+J&rft.au=Godang%2C+K&rft.au=Muller%2C+F&rft.date=2001-12-01&rft.pub=European+Society+of+Endocrinology&rft.issn=0804-4643&rft.eissn=1479-683X&rft.volume=145&rft.issue=6&rft.spage=685&rft.epage=690&rft_id=info:doi/10.1530%2Feje.0.1450685
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0804-4643&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0804-4643&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0804-4643&client=summon